Biotech | July 24, 2023
First of its kind screening for Glaucoma at grass root level over 10k screened already
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The new facility at Dombivli is the fifth ASG Eye Hospital in Maharashtra
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Subscribe To Our Newsletter & Stay Updated
